Pyxis Oncology Files 8-K for Shareholder Vote & Exhibits

TL;DR

Pyxis Oncology filed an 8-K for shareholder votes and financials - check for details.

AI Summary

Pyxis Oncology, Inc. filed an 8-K on October 23, 2024, to report on the submission of matters to a vote of security holders and financial statements and exhibits. The filing does not contain specific details on the matters voted upon or the financial statements themselves, but indicates they are part of the report.

Why It Matters

This filing signals that Pyxis Oncology is engaging in corporate governance activities requiring shareholder approval and is providing updated financial information, which is crucial for investors to assess the company's status.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new material risks or significant negative events.

Key Players & Entities

• Pyxis Oncology, Inc. (company) — Registrant
• October 23, 2024 (date) — Date of earliest event reported
• 321 Harrison Avenue, Boston, Massachusetts 02118 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share PYXS The Nasdaq Global Se

Filing Documents

• pyxs-20241023.htm (8-K) — 54KB
• 0000950170-24-116698.txt ( ) — 170KB
• pyxs-20241023.xsd (EX-101.SCH) — 25KB
• pyxs-20241023_htm.xml (XML) — 5KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On October 23, 2024, Pyxis Oncology, Inc. (the "Company") held its Special Meeting of Stockholders at 10:00 a.m. Eastern Daylight Time in a virtual format via live audio webcast (the "Special Meeting"). The Company set September 9, 2024, as the record date for the Special Meeting and there were a total of 59,422,945 shares of common stock outstanding and entitled to vote at the Special Meeting. At the beginning of the Special Meeting, 36,189,305 shares of common stock were present virtually, in person or by proxy, and, therefore, a quorum was present. At the Special Meeting, the stockholders' voted and approved the amendment to the 2021 Equity and Incentive Plan to increase the available shares by 5,500,000 shares and the adjournment of the Special Meeting, if necessary, in the reasonable discretion of the Chairperson of the Board, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Plan Amendment. The final results of the stockholders' votes at the Special Meeting are set forth below: Proposal One: Approval of an amendment to the 2021 Equity and Incentive Plan to increase the available shares by 5,500,000 shares. For Against Withheld Broker Non-Votes 23,234,250 12,829,636 125,419 0 Proposal Two: Approval of the adjournment of the Special Meeting, if necessary, in the reasonable discretion of the Chairperson of the Board, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Plan Amendment. For Against Withheld Broker Non-Votes 24,209,361 11,893,764 86,180 0 Although Proposal Two was approved, adjournment of the Special Meeting was unnecessary because there was a quorum present and there were sufficient votes received at the time of the Special Meeting to Proposal One.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 First Amendment to Pyxis Oncology, Inc. 2021 Equity and Incentive Plan (incorporated by reference to Appendix A-1 to the Company's Definitive Proxy Statement on Schedule 14A filed on September 25, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Pyxis Oncology, Inc. Date: October 23, 2024 By: /s/ Pamela Connealy Pamela Connealy Chief Financial Officer and Chief Operating Officer